By: CURE Staff
From: curetoday.com
A roundup of the latest news and updates for patients with metastatic breast cancer from CURE®.
There have been several updates in the field of metastatic breast cancer over the last several weeks.
Here, CURE® looks back at some of the latest news and updates affecting patients with metastatic breast cancer.
– Metastatic breast cancer creates a high economic burden, especially among women aged 45 years to 64 years, through lost productivity, according to the results of a productivity cost analysis published in Cancer.
– The combination of pyrotinib plus Xeloda (capecitabine) provides a better progression-free survival (PFS) rate than Tykerb (lapatinib) plus Xeloda in patients with HER2-positive metastatic breast cancer (mBC) who were previously treated with Herceptin (trastuzumab) and chemotherapy, according to recent data.
– First-line treatment with Keytruda (pembrolizumab) in combination with chemotherapy improves progression-free survival in patients with locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC), according to data presented at the 2020 ASCO Virtual Scientific Program.
– The phase 3 Impassion131 study — designed to evaluate the immunotherapy Tecentriq (atezolizumab) in combination with the chemotherapy paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer (TNBC) — failed to meet its primary endpoint of improving progression-free survival, compared with placebo plus paclitaxel.
– Recently, updated findings of the phase 2 HER2CLIMB study demonstrated that patients with HER2-positive metastatic breast cancer who developed brain metastases experienced a 52% reduction in the risk of death after receiving the combination of Tukysa (tucatinib), Herceptin (trastuzumab) and capecitabine.
Barbara Jacoby is an award winning blogger that has contributed her writings to multiple online publications that have touched readers worldwide.